Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Capital Employed (2020 - 2025)

Apellis Pharmaceuticals has reported Return on Capital Employed over the past 6 years, most recently at 0.07% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.07% for Q4 2025, up 13.0% from a year ago — trailing twelve months through Dec 2025 was 0.07% (up 13.0% YoY), and the annual figure for FY2025 was 0.08%, up 15.0%.
  • Return on Capital Employed for Q4 2025 was 0.07% at Apellis Pharmaceuticals, down from 0.31% in the prior quarter.
  • Over the last five years, Return on Capital Employed for APLS hit a ceiling of 0.31% in Q3 2025 and a floor of 0.92% in Q4 2022.
  • Median Return on Capital Employed over the past 5 years was 0.18% (2022), compared with a mean of 0.27%.
  • Biggest five-year swings in Return on Capital Employed: plummeted -71bps in 2023 and later skyrocketed 113bps in 2024.
  • Apellis Pharmaceuticals' Return on Capital Employed stood at 0.27% in 2021, then crashed by -234bps to 0.92% in 2022, then soared by 78bps to 0.2% in 2023, then surged by 71bps to 0.06% in 2024, then skyrocketed by 228bps to 0.07% in 2025.
  • The last three reported values for Return on Capital Employed were 0.07% (Q4 2025), 0.31% (Q3 2025), and 0.11% (Q2 2025) per Business Quant data.